Captor Therapeutics Sa · GPW:CTX
Captor Therapeutics Sa — Q3 2021 Earnings Presentation
24 slides from Captor Therapeutics Sa's earnings presentation, Nov 29, 2021
Slide 1: Presentation of results 3Q 2021
Presentation of results 3Q 2021 29th November 2021 All images by Piotr Piatek
Slide 2: Legal notice
Legal notice This document and the information contained herein (unless otherwise indicated) have been prepared by Captor Therapeutics S.A. (the “Issuer”) solely for informational purposes. For this notice, the presentation that follows shall mean and include the slides that follow, the oral present
Slide 3: Agenda
Agenda • KEY EVENTS IN 3Q’2021, INCLUDING MCL-1 ANNOUNCEMENT • COMPANY STRATEGY & TEAM • SUMMARY ECONOMIC AND FINANCIAL DATA • APPENDIX 3
Slide 4: 3Q'2021 – key take-aways
3Q’2021 – key take-aways BUSINESS in a BRIEF Q3 2021 • MCL-1 – break-through – announcement of the drug target • 3 – active participation in two prestigious • +49 % ** (Q3’2021/Q3’2020) – increased R&D spending conferences: 4th Annual Targeted Protein • 236 M PLN - available funding secured; cash bu
Slide 5: KEY EVENTS in 3Q 2021
KEY EVENTS in 3Q 2021 5
Slide 6: MCL-1 – a high potential drug target
MCL-1 – a high potential drug target MCL-1 has been a subject of intense research MCL-1 protects for many years, but no approved cancer cells drug exists from death CT-03 degraders Captor has address multiple developed diseases, as MCL- CANCER potent 1 is frequently SURVIVAL compounds that altered i
Slide 7: Strong MCL-1 degradation and apoptosis in vivo
Strong MCL-1 degradation and apoptosis in vivo Captor obtained and verified results showing that the Company’s compounds potently degrade Induced Myeloid Leukaemia Cell Differentiation Protein (MCL-1) across a wide range of cancer cell lines. The results obtained demonstrate the following properties
Slide 8: Conferences held
Captor Therapeutics presents at the most important bio-tech meetings in the industry Presentation in Boston (US) by One to one presentations at the CONFERENCES HELD Chief Scientific Officer Dr. Michal BioEurope Meeting by CEO Dr. Tom 4TH ANNUAL Walczak, entitled: "New Shepherd - one of the main TARG
Slide 9: Company pipeline projects
Company pipeline projects # Indications Modality Discovery Preclinical* INDFiling FIH** PROJEKT WSKAZANIE KLASA ZWIĄZKU ODKRYCIE I ROZWÓJ FAZA PRZEDKLINICZNA* FIH** Hepatocellular CT-01 carcinoma MG Autoimmunity Rak wątrobowo - CT-02 MG MG 2023 203 Liquid tumors komórkowy Liquid & solid CT-03 tumors
Slide 10: A growing team of accomplished professionals and significant research spending
A growing team of accomplished professionals and significant research spending favour Captor’s rapid development 7% increase in employees Highly attractive employee 49% increase in R&D operational stock plan for all employees costs (3Q’2021-3Q’2020) 236 M PLN funding secured for 44% - percentage of
Slide 11: COMPANY STRATEGY
COMPANY STRATEGY 11
Slide 12: An ideal pharmaceutical synergy between Poland and Switzerland
Captor Therapeutics: an ideal pharmaceutical synergy between Poland and Switzerland Combine international expertise in A globally connected pharmaceutical Poland has highly qualified scientific Switzerland with local talent in Poland hub staff Access to experienced Polish cost base allows capital Le
Slide 13: Vision – become a world-leading drug discovery company based on targeted protein degradation
Vision – become a world-leading drug discovery company based on targeted protein degradation ❖ Based in Wroclaw (Poland) and Basel (Switzerland) Wroclaw, Poland Basel, Switzerland ❖ Backed by private and non-dilutive public funds as well as funds raised in recent IPO ❖ Disruptive platform in drug di
Slide 14: An experienced leadership team
An experienced leadership team The Company is distinguished by an experienced leadership team with significant experience and clear responsibilities in innovation, commercialization of biopharmaceutical projects, operations and finance MANAGEMENT BOARD CO-FOUNDER Tom Shepherd, Ph.D. Michal Walczak,
Slide 15: Three pillars of growth
Three pillars of growth The continued development of the platform provides a continuous & Platform sustainable flow of new drug development pipeline projects as pipeline drugs are commercialized Develop and Captor focuses on severe diseases commercialize where there are a lack of drug satisfactory t
Slide 16: The Biotechnology industry continues to advance
The Biotechnology industry continues to advance Targeted Protein Degradation (TPD) is a new chapter in the development of the Biotechnology industry Value of equity raised in Biotech • In 2020 IPOs of biopharmaceutical companies raised $73 $140 billion, or 54% of all capital raised $120 • A clear up
Slide 17: SUMMARY ECONOMIC AND FINANCIAL DATA
SUMMARY ECONOMIC AND FINANCIAL DATA 17
Slide 18: Selected financial data
Selected financial data REVENUES AND FINANCIAL RESULTS (PLN thousands) Full 3Q of 2021 Full 3Q of 2020 Operating cost structure for 9M’2021: 22% Research and development income 2 707 - • 56% - R&D expenditure • 22% - Project overheads 56% Other operating income 15 620 14 712 • 22% - General and admi
Slide 19: Strong balance sheet and investments as foundation for further development
Strong balance sheet and investments as foundation for further development Data as of 30/09/2021 HIGHLY QUALIFIED PERSONNEL 1. Number of employees 97 7%* employment increase Number of research workers 80 Percentage of scientists with PhD 44% TANGIBLE FIXED ASSETS ❖ Fixed assets as at 30/09/2021 amou
Slide 20: APPENDIX
APPENDIX 20
Slide 21: Key milestones
Stages of the research & development process Lead Candidate IND First in selection selection submission human Target selection Approval KEY MILESTONES ASSAYS LEAD PRECLINICAL CLINICAL PHASE II AND HIT-TO-LEAD IND REVIEW CLINICAL PHASE I AND SCREENING OPTIMIZATION DEVELOPMENT CLINICAL PHASE III TIMEL
Slide 22: Selected financial data
Selected financial data (data in thous. PLN) INTERIM CONDENSED CONSOLIDATED STATEMENT OF PERFORMANCE AND OTHER COMPREHENSIVE INCOME 01.01.2021- 01.01.2020- 30.09.2021 30.09.2020 Research and development income 2 707 - Cost of services sold 482 - Gross profit (loss) on sales 2 225 - Operating profit
Slide 23: Captor Therapeutics S.A ul. Duńska 11 54-427 Wrocław, Poland
Captor Therapeutics S.A ul. Duńska 11 54-427 Wrocław, Poland Captor Therapeutics GmbH Gewerbestrasse 24 4123 Allschwil, Switzerland IR Contact: Marta Święcicka m.swiecicka@captortherapeutics.com Media and IR Contact: captortherapeutics@pov.pl All images by Piotr Piatek
Slide 24: Projects are co-financed by the European Regional Development Fund
Projects are co-financed by the European Regional Development Fund: Discovery and development of a new clinical drug candidate for the eradication of cancer stem cell in the treatment of hepatocellular carcinoma, through degradation of oncofetal transcription factor (POIR.01.01.01-00-0740/19) Discov